Savara

SVRA53

Penny Stock

$3.36arrow_drop_up3.54%$0.11

Penny Stock

SVRA53

$3.36

arrow_drop_up3.54%$0.11

Penny Stock

Performance History

Key Stats
Open	$3.23
Prev. Close	$3.24
EPS	-0.43
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$576.63M
PE Ratio	-

	LOW	HIGH
Day Range	3.21	3.42
52 Week Range	2.82	5.70

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.43

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Savara (SVRA)

Savara Inc (SVRA) is a pharmaceutical company that specializes in developing and commercializing novel therapies for patients with rare respiratory diseases. The company is focused on addressing unmet medical needs in conditions such as pulmonary nontuberculous mycobacterial (NTM) infection, cystic fibrosis, and asthma. With a diverse portfolio of drug candidates, Savara aims to provide innovative treatment options for patients suffering from these debilitating conditions.

The stock price history of Savara Inc (SVRA) reflects the company's journey in the highly dynamic pharmaceutical industry. Over the years, the stock has experienced fluctuations influenced by various factors such as clinical trial results, regulatory milestones, and market sentiment. Investors in SVRA have witnessed both ups and downs in the stock's value, highlighting the inherent volatility of the healthcare sector.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Matthew Pauls
Headquarters: Austin
Employees: 28
Exchange: NASDAQ

Keep an eye on Savara

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Savara 's (SVRA) price per share?

The current price per share for Savara (SVRA) is $3.36. The stock has seen a price change of $0.11 recently, indicating a 3.55% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Savara (SVRA)?

For Savara (SVRA), the 52-week high is $5.7, which is 69.64% from the current price. The 52-week low is $2.82, the current price is 19.15% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Savara (SVRA) a growth stock?

Savara (SVRA) has shown an average price growth of -3.66% over the past three years. It has received a score of 89 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Savara as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Savara (SVRA) stock price performance year to date (YTD)?

As of the latest data, Savara (SVRA) has a year-to-date price change of -23.11%. Over the past month, the stock has experienced a price change of 0.6%. Over the last three months, the change has been -22.4%. Over the past six months, the figure is -17.65%. Looking at a longer horizon, the five-year price change stands at 220%.

help

Is Savara (SVRA) a profitable company?

Savara (SVRA) has a net income of -$54.7M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$60.01M. Furthermore, the EBITDA is -$88.72M.

help

What is the market capitalization of Savara (SVRA)?

Savara (SVRA) has a market capitalization of $576.64M. The average daily trading volume is 3.36, indicating the stock's liquidity and investor engagement.

News

SAVARA

MOLBREEVI

RARE RESPIRATORY DISEASES

HEALTHCARE CONFERENCES

Nov 13, 2024

Savara Announces Participation in Upcoming Healthcare Conferences

SAVARA

AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of "The Balancing Act®" Airing on Lifetime® TV

Jun 2, 2024

Wall Street Breakfast: The Week Ahead

Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday

NEWS